These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 730486)

  • 21. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 22. Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety.
    Laughren T
    Clin Ther; 1998; 20 Suppl C():C12-9. PubMed ID: 9915085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 25. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives.
    Cutler NR; Sramek JJ; Greenblatt DJ; Chaikin P; Ford N; Lesko LJ; Davis B; Williams RL
    J Clin Pharmacol; 1997 Sep; 37(9):767-83. PubMed ID: 9549630
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase 3 trials and drug labeling.
    Am J Cardiol; 1974 Oct; 34(4):481-2. PubMed ID: 4415044
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.
    Mitka M
    JAMA; 2012 Jun; 307(24):2576-7. PubMed ID: 22735406
    [No Abstract]   [Full Text] [Related]  

  • 28. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The promise of pharmacoepidemiology.
    Strom BL
    Annu Rev Pharmacol Toxicol; 1987; 27():71-86. PubMed ID: 3555321
    [No Abstract]   [Full Text] [Related]  

  • 30. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system.
    Rossi AC; Knapp DE
    JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing surveillance of new drugs: I. Review of objectives and methodology.
    Wardell WM; Tsianco MC; Anavekar SN; Davis HT
    J Clin Pharmacol; 1979; 19(2-3):85-94. PubMed ID: 370159
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 33. In drug research, some guinea pigs are now human.
    Pollack A
    N Y Times Web; 2004 Aug; ():A1, C3. PubMed ID: 15497234
    [No Abstract]   [Full Text] [Related]  

  • 34. Proceedings of the National Conference on Clinical Trials Methodology.
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):629-766. PubMed ID: 35299
    [No Abstract]   [Full Text] [Related]  

  • 35. [Planning of psychotropic drug trials. Statistical evaluation. Hypotheses and methods].
    Immich H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 May; 10(3):185-92. PubMed ID: 30098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovering adverse drug reactions.
    Lasagna L
    JAMA; 1983 Apr 22-29; 249(16):2224-5. PubMed ID: 6339764
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug hepatotoxicity from a regulatory perspective.
    Senior JR
    Clin Liver Dis; 2007 Aug; 11(3):507-24, vi. PubMed ID: 17723917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rater-specific interference factors in clinical trials (author's transl)].
    Busch H
    Pharmakopsychiatr Neuropsychopharmakol; 1977 May; 10(3):152-62. PubMed ID: 360240
    [No Abstract]   [Full Text] [Related]  

  • 39. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions.
    Hutchinson TA; Flegel KM; HoPingKong H; Bloom WS; Kramer MS; Trummer EG
    Clin Pharmacol Ther; 1983 Oct; 34(4):421-6. PubMed ID: 6617062
    [No Abstract]   [Full Text] [Related]  

  • 40. Medication monitoring in the workplace: toward improving our system of epidemiologic intelligence.
    Tilson HH
    J Occup Med; 1990 Apr; 32(4):313-9. PubMed ID: 2335797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.